Replies to post #114194 on Biotech Values

[exwannabe]

Re: DEPO

They are a sound company that has executed well, but they have a small game.

Talking about a 2B market is a little misleading when they are caught between Lyreca (which is viewed as a better drug by many) and cheap generic gabas.

There is a reason that ABT was talking about dropping it. I predict that will not happen (ABT will just launch) but obviously they do not think this is some $500m/y drug.

But DEPO keeps costs reasonable, is growing revenue, and all indications are that it's core platform does work.

This is quickly going to become a revenue play. That might be good, but it is not going to be some home run.

For non-followers: DEPO's game is an extended release technology.